To this end, we conducted a systematic review and meta-analyses of the latest randomized controlled trials (RCTs) and observational studies (cohort and case–control studies) published in the last 10 years that evaluated the effect of diabetes medications, namely biguanides, incretin-based medicines, alpha-glucosidase inhibitors (AGIs), insulin secretagogues, thiazolidinediones, and insulins, on the risk of developing any of study cancers, specifically breast, lung, colorectal, prostate, liver, or pancreatic cancers. The gene discussed is INS; the disease is familial pancreatic carcinoma.